



| Report Number: | 22-002509/D006.R000 |
|-----------------|---------------------|
| Report Date: | 03/09/2022 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 03/03/22 16:51 |

| Customer: | IHC LLC |
|-------------------|----------------|
| Product identity: | 01020506LIRFV |
| Client/Metrc ID: | |
| Laboratory ID: | 22-002509-0002 |

Summary

| Analyte | Result (%) | • CBG • CB | | |
|---------------------|------------|---------------|-----------------|------------------------|
| CBG [†] | 37.1 | • CBD | CBD-Total | 24.9% |
| CBD | 21.0 | CBD-A | | |
| CBD-A | 4.46 | • CBC | THC-Total | <loq< td=""></loq<> |
| CBC | 3.73 | CBDV | | |
| CBDV [†] | 3.56 | CBT CBDV-A | (Reported in pe | rcent of total sample) |
| CBT⁺ | 3.12 | • CBN | | |
| CBDV-A [†] | 3.08 | • CBE | | |
| CBN | 2.16 | 8-THCV | | |
| CBE [†] | 2.03 | THCV | | |
| ∆8-THCV | 1.90 | | | |
| THCV [†] | 0.173 | | | |
| CBL [†] | 0.170 | | | |

 Www.columbialaboratories.com
 Page 1 of 7

 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.

 Testing in accordance with:
 OAR 333-007-0430





| Customer: | IHC LLC 825 NW 16th Ave Portland Oregon 97209 United States of America (USA) |
|----------------------|---|
| Product identity: | 01020506LIRFV |
| Client/Metrc ID: | |
| Sample Date: | |
| Laboratory ID: | 22-002509-0002 |
| Evidence of Cooling: | No |
| Temp: | 19.4 °C |
| Relinquished by: | Client |

Report Number: 22-002509/D006.R000 **Report Date:** 03/09/2022 **ORELAP#:** OR100028 **Purchase Order:** Received: 03/03/22 16:51



THE HEMP COLLECT

Sample Results

| Potency | Method J | AOAC 2015 V9 | 8-6 (mod) | Units % | Batch: 2202014 | Analyze: 3/9/22 | 9:13:00 | AM |
|---------------------------------|----------|--------------|-----------|---------|----------------|-----------------|--|------|
| Analyte | | Dry LOQ | Notes | | | | | |
| | | weight | | | | | CBG | THCV |
| CBC | 3.73 | 0.0894 | | | | | CBD | CBL |
| CBC-A [†] | < LOQ | 0.0894 | | | | | CBD-A CBC | |
| CBC-Total [†] | 3.73 | 0.168 | | | | | CBC | |
| CBD | 21.0 | 0.0894 | | | | | CBT | |
| CBD-A | 4.46 | 0.0894 | | | | | CBDV-A | |
| CBD-Total | 24.9 | 0.168 | | | | | CBN | |
| CBDV [†] | 3.56 | 0.0894 | | | | | CBE | |
| CBDV-A [†] | 3.08 | 0.0894 | | | | | 8-THCV | |
| CBDV-Total [†] | 6.23 | 0.167 | | | | | | |
| CBE [†] | 2.03 | 0.0894 | | | | | | |
| CBG [†] | 37.1 | 0.894 | | | | | | |
| CBG-A [†] | < LOQ | 0.0894 | | | | | | |
| CBG-Total | 37.1 | 0.971 | | | | | | |
| CBL [†] | 0.170 | 0.0894 | | | | | | |
| CBL-A [†] | < LOQ | 0.0894 | | | | | | |
| CBL-Total [†] | 0.170 | 0.168 | | | | | | |
| CBN | 2.16 | 0.0894 | | | | | | |
| CBT [†] | 3.12 | 0.0894 | | | | | | |
| $\Delta 8\text{-THC}^{\dagger}$ | < LOQ | 0.0894 | | | | | | |
| ∆8-THCV | 1.90 | 0.0894 | | | | | | |
| ∆9-THC | < LOQ | 0.0894 | | | | | | |
| THC-A | < LOQ | 0.0894 | | | | | | |
| THC-Total | < LOQ | 0.168 | | | | | | |
| THCV [†] | 0.173 | 0.0894 | | | | | | |
| THCV-A [†] | < LOQ | 0.0894 | | | | | | |
| THCV-Total [†] | 0.173 | 0.167 | | | | | | |
| Total Cannabinoids [†] | 82.5 | | | | | | | |

 Www.columbialaboratories.com
 Page 2 of 7

 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.

 Testing in accordance with:
 OAR 333-007-0430





 Report Number:
 22-002509/D006.R000

 Report Date:
 03/09/2022

 ORELAP#:
 OR100028

 Purchase Order:
 Received:

 03/03/22 16:51

These test results are representative of the individual sample selected and submitted by the client.

Abbreviations

Limits: Action Levels per OAR-333-007-0400, OAR-333-007-0210, OAR-333-007-0220, CCR title 16-division 42. BCC-section 5723

Limit(s) of Quantitation (LOQ): The minimum levels, concentrations, or quantities of a target variable (e.g., target analyte) that can be reported with a specified degree of confidence.

[†] = Analyte not NELAP accredited.

Units of Measure

% = Percentage of sample % wt = $\mu g/g$ divided by 10,000

Approved Signatory

Derrick Tanner General Manager

www.columbialaboratories.com

Page 3 of 7

Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.



Columbia LABORATORIES

12423 NE Whitaker Way Portland, OR 97230 503-254-1794



Hemp / Cannabis Usable / Extract / Finished Products

Chain of Custody Record

Report Number: 22-002509/D006.R000 **Report Date:** 03/09/2022 **ORELAP#:** OR100028 Purchase Order:

Received:

03/03/22 16:51

| | | | | | | A | Analysi | is Req | ueste | d | | | | P | O Number: | |
|--|---|-----------------|---|-----------|---------|---------------------------|----------|-----------------------|------------------------------------|-------------------|--------------|------------|---|------------------|-------------------|--|
| Company: Kyle Farook Street: Street: Generating the farook City: Portland State: DF Email Results: Global State: OF Ph: OBLIG: State: OF State:< | | JR 59 compounds | esticide Multi-Residue – 379 compounds | | olvents | Moisture & Water Activity | | Vicro: Yeast and Mold | vlicro: E. Coli and Total Coliform | un anu rua comoni | S | | Project Number: Project Name: Custom Reporting: Report to State - □ METRC or □ Other: Turnaround time: 1 5 Business Day Standard Turnaround □ 3 Business Day Rush Turnaround* □ 2 Business Day Rush Turnaround* *Check for availability Sampled by: | | | |
| b Client Sample Identification | Date | Time | Pesticides – (| Pesticide | Potency | Residual Solvents | Moisture | Terpenes | Micro: Ye | 6 | Heavy Metals | Mycotoxins | Other: | Sample Type † | Weight (Units) | Comments/Metrc ID |
| 12ISO | 3/3 | | | N. | X | AN IN | | | | | No. | | | | | -Please return remainder of sample #1 % client. |
| 01020506LIRFV | 3/3 | | | | x | | | | | | | | | | | - Crease I Creatin |
| 01020506LIRTG 0103FTS101 Lifter | 3/3 | | | | X | | | | | | | | | | | remainder of |
| 0103FTS101_Lifter | 3/3 | | | | X | | | | | | | | | | | sample #1 to |
| 0103FTS103_LegendC | 3/3 | | | | x | | | | | | | | | | | |
| 0103FTS103_Gushers | 3/3 | | | | X | | | | | | | | | | | dient. |
| 01FLT113_GF | 3/3 | | | | X | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Relinquished By: | Date | Time | | | R | eceived | By: | | | Da | ate | Ti | me | | | Lab Use Only: |
| yle Farook | Evidence of cooling: Yes Sample in good condition? | | or'BClient drop] Yes DNo - Temp (°C): <u> 9, </u> | | | | | | | | | | | | | |

+ - Sample Type Codes: Vegetation (V) ; Isolates (S) ; Extract/Concentrate (C) ; Tincture/Topical (T) ; Edible (E) ; Beverage (B)

Samples submitted to Columbia Laboratories with testing requirements constitute an agreement for services in accordance with the current terms of service associated with this COC. By signing "Relinquished by" you are agreeing to these terms 3 NE Whitaker Way P: (503) 254-1794 | Fax: (503) 254-1794 | Fax: (503) 254-1795 Page _____of____ www.columbialaboratories.com 12423 NE Whitaker Way Portland, OR 97230 info@columbialaboratories.com

Page 4 of 7

Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.





Report Number: 22-002509/D006.R000 03/09/2022 **Report Date: ORELAP#:** OR100028 Purchase Order:

Received:

03/03/22 16:51

Revision: 1 Document ID: 7148

Legacy ID: Worksheet Validated 04/20/2021

| | | Labor | atory (| Quality Co | ontrol Results | | | | | |
|----------------|--------------------------|-------|---------|------------|----------------|--------------|-------|--|--|--|
| J AOAC 2015 V | 98-6 | | | Bat | ch ID: 2202014 | 1 | | | | |
| Laboratory Cor | aboratory Control Sample | | | | | | | | | |
| Analyte | Result | Spike | Units | % Rec | Limits | Evaluation | Notes | | | |
| CBDVA | 0.201 | 0.200 | % | 100 | 80.0 - 12 | 0 Acceptable | | | | |
| CBDV | 0.223 | 0.200 | % | 112 | 80.0 - 12 | 0 Acceptable | | | | |
| CBE | 0.195 | 0.200 | % | 97.5 | 80.0 - 12 | 0 Acceptable | | | | |
| CBDA | 0.215 | 0.200 | % | 107 | 80.0 - 12 | 0 Acceptable | | | | |
| CBGA | 0.198 | 0.200 | % | 98.9 | 80.0 - 12 | 0 Acceptable | | | | |
| CBG | 0.208 | 0.200 | % | 104 | 80.0 - 12 | 0 Acceptable | | | | |
| CBD | 0.211 | 0.200 | % | 105 | 80.0 - 12 | 0 Acceptable | | | | |
| THCV | 0.192 | 0.200 | % | 96.0 | 80.0 - 12 | 0 Acceptable | | | | |
| d8THCV | 0.204 | 0.200 | % | 102 | 80.0 - 12 | 0 Acceptable | | | | |
| THCVA | 0.196 | 0.200 | % | 97.8 | 80.0 - 12 | 0 Acceptable | | | | |
| CBN | 0.211 | 0.200 | % | 105 | 80.0 - 12 | 0 Acceptable | | | | |
| exo-THC | 0.184 | 0.200 | % | 92.2 | 80.0 - 12 | 0 Acceptable | | | | |
| d9THC | 0.201 | 0.200 | % | 100 | 80.0 - 12 | 0 Acceptable | | | | |
| d8THC | 0.198 | 0.200 | % | 98.9 | 80.0 - 12 | 0 Acceptable | | | | |
| CBL | 0.188 | 0.200 | % | 94.0 | 80.0 - 12 | 0 Acceptable | | | | |
| CBC | 0.203 | 0.200 | % | 101 | 80.0 - 12 | 0 Acceptable | | | | |
| THCA | 0.204 | 0.200 | % | 102 | 80.0 - 12 | 0 Acceptable | | | | |
| CBCA | 0.202 | 0.200 | % | 101 | 80.0 - 12 | 0 Acceptable | | | | |
| CBLA | 0.204 | 0.200 | % | 102 | 80.0 - 12 | 0 Acceptable | | | | |
| CBT | 0.182 | 0.200 | % | 91.1 | 80.0 - 12 | 0 Acceptable | | | | |

Method Blank

| Analyte | Result | LOQ | Units | Limits | Evaluation | Notes |
|---------|--------|-----|-------|--------|------------|-------|
| CBDVA | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBDV | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBE | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBDA | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBGA | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBG | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBD | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| THCV | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| d8THCV | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| THCVA | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBN | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| exo-THC | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| d9THC | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| d8THC | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBL | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBC | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| THCA | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBCA | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBLA | < LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBT | < LOQ | 0.1 | % | < 0.1 | Acceptable | |

Abbreviations

ND - None Detected at or above MRL RPD - Relative Percent Difference

LOQ - Limit of Quantitation

Units of Measure:

% - Percent

Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.





| Report Number: | 22-002509/D006.R000 |
|-----------------|---------------------|
| Report Date: | 03/09/2022 |
| ORELAP#: | OR100028 |
| Purchase Order: | |

Received:

03/03/22 16:51

Revision: 1 Document ID: 7148

| Legacy ID: Wor | ksheet Validated | 04/20/2021 |
|----------------|------------------|------------|
|----------------|------------------|------------|

| | | | Labor | atorv | Quality Co | ntrol Results | | |
|-------------|--------|-------------|-------|-------|------------|---------------|------------|-------|
| J AOAC 2015 | V98-6 | | | | | h ID: 2202014 | | |
| Sample Dupl | icate | | | | | | | |
| Analyte | Result | Org. Result | LOQ | Units | RPD | Limits | Evaluation | Notes |
| CBDVA | < LOQ | < LOQ | 0.1 | % | NA | < 20 | Acceptable | |
| CBDV | 0.347 | 0.350 | 0.1 | % | 0.874 | < 20 | Acceptable | |
| CBE | 0.853 | 0.864 | 0.1 | % | 1.31 | < 20 | Acceptable | |
| CBDA | < LOQ | < LOQ | 0.1 | % | NA | < 20 | Acceptable | |
| CBGA | < LOQ | < LOQ | 0.1 | % | NA | < 20 | Acceptable | |
| CBG | 0.762 | 0.762 | 0.1 | % | 0.0262 | < 20 | Acceptable | |
| CBD | 67.2 | 65.8 | 0.1 | % | 2.11 | < 20 | Acceptable | |
| THCV | < LOQ | < LOQ | 0.1 | % | NA | < 20 | Acceptable | |
| d8THCV | < LOQ | < LOQ | 0.1 | % | NA | < 20 | Acceptable | |
| THCVA | < LOQ | < LOQ | 0.1 | % | NA | < 20 | Acceptable | |
| CBN | 0.747 | 0.815 | 0.1 | % | 8.73 | < 20 | Acceptable | |
| exo-THC | < LOQ | < LOQ | 0.1 | % | NA | < 20 | Acceptable | |
| d9THC | 0.336 | 0.211 | 0.1 | % | 45.6 | < 20 | Outlier | R |
| d8THC | < LOQ | < LOQ | 0.1 | % | NA | < 20 | Acceptable | |
| CBL | < LOQ | < LOQ | 0.1 | % | NA | < 20 | Acceptable | |
| CBC | 2.98 | 3.04 | 0.1 | % | 2.10 | < 20 | Acceptable | |
| THCA | < LOQ | < LOQ | 0.1 | % | NA | < 20 | Acceptable | |
| CBCA | < LOQ | < LOQ | 0.1 | % | NA | < 20 | Acceptable | |
| CBLA | < LOQ | < LOQ | 0.1 | % | NA | < 20 | Acceptable | |
| CBT | 0.440 | 0.446 | 0.1 | % | 1.18 | < 20 | Acceptable | |

Abbreviations

- ND None Detected at or above MRL
- RPD Relative Percent Difference

LOQ - Limit of Quantitation

Units of Measure:

% - Percent

 Www.columbialaboratories.com
 Page 6 of 7

 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.

 Testing in accordance with:
 OAR 333-007-0430





Report Number: 22-002509/D006.R000 **Report Date:** 03/09/2022 **ORELAP#:** OR100028 **Purchase Order: Received:** 03/03/22 16:51

Explanation of QC Flag Comments:

| Code | Explanation |
|------|---|
| Q | Matrix interferences affecting spike or surrogate recoveries. |
| Q1 | Quality control result biased high. Only non-detect samples reported. |
| Q2 | Quality control outside QC limits. Data considered estimate. |
| Q3 | Sample concentration greater than four times the amount spiked. |
| Q4 | Non-homogenous sample matrix, affecting RPD result and/or % recoveries. |
| Q5 | Spike results above calibration curve. |
| Q6 | Quality control outside QC limits. Data acceptable based on remaining QC. |
| R | Relative percent difference (RPD) outside control limit. |
| R1 | RPD non-calculable, as sample or duplicate results are less than five times the LOQ. |
| R2 | Sample replicates RPD non-calculable, as only one replicate is within the analytical range. |
| LOQ1 | Quantitation level raised due to low sample volume and/or dilution. |
| LOQ2 | Quantitaion level raised due to matrix interference. |
| В | Analyte detected in method blank, but not in associated samples. |
| B1 | The sample concentration is greater than 5 times the blank concentration. |
| B2 | The sample concentration is less than 5 times the blank concentration. |

Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430